CFO of Cardlytics (NASDAQ: CDLX) makes 200K-share open-market buy

Filing Impact

(High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Cardlytics, Inc. Chief Financial Officer David Thomas Evans reported open-market purchases of a total of 200,000 shares of common stock. He bought 150,000 shares on May 15, 2026 at a weighted average price of $0.649 per share and 50,000 shares on May 18, 2026 at a weighted average price of $0.633 per share.

Both trades were direct, non-derivative purchases. After these transactions, Evans directly owned 317,930 shares of Cardlytics common stock. Footnotes explain that each reported price is a weighted average across multiple individual trades executed within narrow price ranges on the respective dates.

Insider Trade Summary

Net Buyer: 200,000 shares ($129,000)

Net Buy 2 txns

Insider Evans David Thomas

Role Chief Financial Officer

Bought 200,000 shs ($129K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	50,000	$0.633	$32K
Purchase	Common Stock	150,000	$0.649	$97K

Holdings After Transaction: Common Stock — 317,930 shares (Direct, null)

Footnotes (1)

The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.639 to $0.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1). The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.627 to $0.639, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2).

Key Figures

Shares bought May 15, 2026: 150,000 shares Shares bought May 18, 2026: 50,000 shares Total shares bought: 200,000 shares +3 more

6 metrics

Shares bought May 15, 2026 150,000 shares Open-market purchase at $0.649 weighted average price

Shares bought May 18, 2026 50,000 shares Open-market purchase at $0.633 weighted average price

Total shares bought 200,000 shares Sum of May 15 and May 18, 2026 open-market purchases

Holdings after transactions 317,930 shares Direct ownership after May 18, 2026 trade

Price range May 15, 2026 $0.639–$0.650 Weighted average price $0.649 within this range

Price range May 18, 2026 $0.627–$0.639 Weighted average price $0.633 within this range

Key Terms

open-market purchase, weighted average purchase price, non-derivative, reporting person

4 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reported is a weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

non-derivative financial

"transaction_type: non-derivative"

reporting person regulatory

"The Reporting Person undertakes to provide to the Issuer"

Form 4 Insider Transactions: What Each Field Means →

05/19/2026 - 04:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans David Thomas

(Last)

(First)

(Middle)

C/O CARDLYTICS, INC.

675 PONCE DE LEON AVENUE NE, SUITE 4100

(Street)

ATLANTA

GEORGIA

30308

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardlytics, Inc. [ CDLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		P		150,000	A	$0.649⁽¹⁾	267,930	D
Common Stock	05/18/2026		P		50,000	A	$0.633⁽²⁾	317,930	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.639 to $0.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1).

2. The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.627 to $0.639, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2).

Remarks:

	/s/ Nick Lynton, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cardlytics (CDLX) report for its CFO?

Cardlytics reported that CFO David Thomas Evans bought 200,000 common shares. He made two open-market purchases in May 2026, adding to his direct holdings and signaling increased personal exposure to the company’s stock.

How many Cardlytics (CDLX) shares does the CFO hold after these trades?

After the reported transactions, the CFO directly owns 317,930 Cardlytics shares. This figure reflects his position following the May 15 and May 18, 2026 open-market purchases disclosed in the Form 4 filing.

At what prices did the Cardlytics (CDLX) CFO buy shares in May 2026?

The CFO bought shares at weighted average prices of $0.649 and $0.633. The May 15, 2026 purchase averaged $0.649 per share, while the May 18, 2026 purchase averaged $0.633 per share, each based on multiple trades within narrow price ranges.

Were the recent Cardlytics (CDLX) CFO transactions open-market purchases?

Yes, both transactions were classified as open-market purchases of common stock. The Form 4 lists transaction code “P” for each trade, indicating non-derivative, open-market or privately negotiated purchases made directly by the reporting person.

How many Cardlytics (CDLX) shares did the CFO buy on each transaction date?

The CFO purchased 150,000 shares on May 15, 2026 and 50,000 shares on May 18, 2026. Combined, these direct open-market purchases total 200,000 additional Cardlytics common shares reported in the Form 4.